Recent NRBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:30:16 PM
- NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone • PR Newswire (US) • 05/22/2024 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 01:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:05:51 PM
- NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/09/2024 12:01:00 PM
- NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June • PR Newswire (US) • 04/30/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 04/17/2024 12:05:00 PM
- NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 04/01/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/28/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 03/13/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer • PR Newswire (US) • 03/04/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:14 PM
- NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/29/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:52:22 PM
- NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference • PR Newswire (US) • 02/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:15 PM
- NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/01/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:30:23 PM
- NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 01/18/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:45:11 PM
- NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement • PR Newswire (US) • 01/09/2024 01:30:00 PM
- NeuroBo to Participate in Industry and Investor Conferences in January • PR Newswire (US) • 01/02/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 02:00:14 PM
- NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 12/28/2023 01:45:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM